Autochthon Biotechnology
April 2012. April 2012. In order to turn algal biomass into a commodity product current cost is to be significantly brought down. Dr James Flatt, CTO of Synthetic Genomics provides in-depth answers to probing questions by B2Bioworld about SGI’s R&D strategies, its business case, social responsibility and returns to investors – including Agradis and developing countriesReading time: 12 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Cash in Agbio and Food Markets
Jörg Riesmeier, Direvo’s New COO on near- to mid-term strategies
Network intelligence for Lundbeck’s new drugs
Yamaha’s Brazilian Flex-Fuel Bike
Years too late to re-program Honda Moto. What about BMW and e-mobility
Lobbying ethanol plants in the United States - “Some expectations were very aggressive…”
Christopher Standlee, at the time Vice-President Global Affairs for Abengoa Bioenergy US